Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma

Novartis Pharmaceuticals26 enrolled

Overview

This study evaluated the pharmacokinetics of aldesleukin in participants with metastatic renal cell cancer or metastatic melanoma.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Metastatic Renal Cell Carcinoma Metastatic Melanoma

Interventions

AldesleukinDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: * Performance Status Eastern Cooperative Oncology Group: 0 or 1. * Adequate organ function. Exclusion criteria: * Pregnancy or lactation. * Prior treatment with any form of IL-2. * Organ transplant. Other protocol-defined inclusion/exclusion criteria may apply

Locations (4)

USC/Kenneth Norris Comprehensive Cancer Center

Los Angeles, California, United States

University of Colorado Cancer Center

Aurora, Colorado, United States

James Graham Brown Cancer Center

Louisville, Kentucky, United States

Dartmouth Hitchcock Medical Center

Lebanon, New Hampshire, United States

Outcomes

Primary Outcomes

Change in the Area Under the Concentration-Time Curve (AUC) From 0 to 8 Hours (AUC0-8) of Aldesleukin After One Cycle of Therapy

Time frame: From Cycle 1, Day 1 to Cycle 2, Day 15

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.